A blood RNA signature for tuberculosis disease risk: a p

Lancet, The

387, 2312-2322

DOI: 10.1016/s0140-6736(15)01316-1

Citation Report

#	Article	IF	Citations
1	Blood transcriptomic diagnosis of pulmonary and extrapulmonary tuberculosis. JCI Insight, 2016, 1, e87238.	5.0	83
2	Transcriptomic Biomarkers for Tuberculosis: Evaluation of DOCK9. EPHA4, and NPC2 mRNA Expression in Peripheral Blood. Frontiers in Microbiology, 2016, 7, 1586.	3.5	46
3	Tuberculosis Diagnostics: State of the Art and Future Directions. Microbiology Spectrum, 2016, 4, .	3.0	87
4	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. European Respiratory Journal, 2016, 48, 1751-1763.	6.7	165
5	The Role of Host Genetics (and Genomics) in Tuberculosis. Microbiology Spectrum, 2016, 4, .	3.0	31
6	Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. Microbiology Spectrum, 2016, 4, .	3.0	71
7	EFIS lecture. Immune response to tuberculosis: How to control the most successful pathogen on earth. Immunology Letters, 2016, 175, 50-57.	2.5	8
8	Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography. Nature Medicine, 2016, 22, 1090-1093.	30.7	166
9	The Challenge of Latent TB Infection. JAMA - Journal of the American Medical Association, 2016, 316, 931.	7.4	31
10	New tests for detection of Mycobacterium tuberculosis infection: sufficient to meet the WHO 2035 targets?. Future Microbiology, 2016, 11, 1101-1104.	2.0	2
11	Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Research and Therapy, 2016, 13, 34.	1.7	26
12	A Functional Role for Antibodies in Tuberculosis. Cell, 2016, 167, 433-443.e14.	28.9	461
13	First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. European Respiratory Journal, 2016, 48, 1411-1419.	6.7	119
14	T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications, 2016, 7, 11290.	12.8	236
15	Early Whole Blood Transcriptional Signatures Are Associated with Severity of Lung Inflammation in Cynomolgus Macaques with Mycobacterium tuberculosis Infection. Journal of Immunology, 2016, 197, 4817-4828.	0.8	33
16	Predicting tuberculosis risk â€“ Authorsâ€™ reply. Lancet, The, 2016, 388, 2233-2234.	13.7	12
17	Tuberculosis. Nature Reviews Disease Primers, 2016, 2, 16076.	30.5	830
18	Circulating granulysin levels in healthcare workers and latent tuberculosis infection estimated using interferon-gamma release assays. BMC Infectious Diseases, 2016, 16, 580.	2.9	7

#	Article	IF	Citations
19	Predicting tuberculosis risk. Lancet, The, 2016, 388, 2233.	13.7	21
20	Lack of Response to <scp>HBHA</scp> in <scp>HIV</scp>â€Infected Patients with Latent Tuberculosis Infection. Scandinavian Journal of Immunology, 2016, 84, 344-352.	2.7	23
21	Two sizes do not fit all: the terms infection and disease are inadequate for the description of children with tuberculosis. Archives of Disease in Childhood, 2016, 101, 594-595.	1.9	2
22	Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis. Respiration, 2016, 92, 199-214.	2.6	18
23	BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome. Scientific Reports, 2016, 6, 38841.	3.3	8
24	Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research. Clinical Infectious Diseases, 2016, 63, 370-375.	5.8	5
25	Human biomarkers: can they help us to develop a new tuberculosis vaccine?. Future Microbiology, 2016, 11, 781-787.	2.0	9
26	Tuberculosisâ€"advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infectious Diseases, The, 2016, 16, e34-e46.	9.1	223
27	Predicting active tuberculosis progression by RNA analysis. Lancet, The, 2016, 387, 2268-2270.	13.7	9
28	A 10-Gene Signature for the Diagnosis and Treatment Monitoring of Active Tuberculosis Using a Molecular Interaction Network Approach. EBioMedicine, 2017, 16, 22-23.	6.1	2
29	Retrospective study of clinical and lesion characteristics of patients undergoing surgical treatment for Pulmonary Tuberculosis in Georgia. International Journal of Infectious Diseases, 2017, 56, 200-207.	3.3	12
30	Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks. EBioMedicine, 2017, 15, 112-126.	6.1	75
31	Human Immunology of Tuberculosis. Microbiology Spectrum, 2017, 5, .	3.0	101
32	Optimizing the management of children with latent tuberculosis infection. Expert Review of Anti-Infective Therapy, 2017, 15, 341-349.	4.4	4
33	Host-Based Peripheral Blood Gene Expression Analysis for Diagnosis of Infectious Diseases. Journal of Clinical Microbiology, 2017, 55, 360-368.	3.9	65
34	The uncertain science of predicting tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 239-240.	10.7	3
35	Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 282-290.	10.7	110
36	Tuberculosis elimination and the challenge of latent tuberculosis. Presse Medicale, 2017, 46, e13-e21.	1.9	48

#	Article	IF	Citations
37	A tuberculosis biomarker database: the key to novel TB diagnostics. International Journal of Infectious Diseases, 2017, 56, 253-257.	3.3	44
38	New concepts in understanding latent tuberculosis. Current Opinion in Infectious Diseases, 2017, 30, 316-321.	3.1	16
39	Reasons for optimism in the search for new vaccines for tuberculosis. Epidemiology and Infection, 2017, 145, 1750-1756.	2.1	0
40	Quantitative and qualitative iNKT repertoire associations with disease susceptibility and outcome in macaque tuberculosis infection. Tuberculosis, 2017, 105, 86-95.	1.9	16
41	The management of infection withMycobacterium tuberculosisin young children post-2015: an opportunity to close the policy-practice gap. Expert Review of Respiratory Medicine, 2017, 11, 41-49.	2.5	19
42	Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications. Scientific Reports, 2017, 7, 1999.	3.3	92
43	Diagnosis of Tuberculosis in <scp>HIV</scp> Coâ€infected Individuals: Current Status, Challenges and Opportunities for the Future. Scandinavian Journal of Immunology, 2017, 86, 76-82.	2.7	37
44	Systems immunology: just getting started. Nature Immunology, 2017, 18, 725-732.	14.5	194
45	Working together toward vaccines and biomarkers in the real world. Human Vaccines and Immunotherapeutics, 2017, 13, 1492-1494.	3.3	0
46	A review of computational and mathematical modeling contributions to our understanding of Mycobacterium tuberculosis within-host infection and treatment. Current Opinion in Systems Biology, 2017, 3, 170-185.	2.6	61
47	Long-lasting tuberculous pleurisy. European Respiratory Journal, 2017, 49, 1602472.	6.7	2
48	Long-lasting tuberculous pleurisy. European Respiratory Journal, 2017, 49, 1700356.	6.7	3
49	Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers. Expert Review of Vaccines, 2017, 16, 845-853.	4.4	11
50	Sharing the spotlight in Durban: A report from IAS TB2016 at AIDS2016. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017, 7, 34-39.	1.3	0
51	Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home. Clinical and Experimental Immunology, 2017, 188, 226-233.	2.6	13
52	From latent to patent: rethinking prediction of tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 243-244.	10.7	26
53	A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infectious Diseases, The, 2017, 17, 1190-1199.	9.1	75
54	Tuberculosis Vaccines. , 2017, , 1-12.		0

#	Article	IF	Citations
56	Sex differences in the C57BL/6 model of Mycobacterium tuberculosis infection. Scientific Reports, 2017, 7, 10957.	3.3	36
57	Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis, 2017, 107, 48-58.	1.9	156
58	Tuberculosis in Children. Pediatric Clinics of North America, 2017, 64, 893-909.	1.8	70
59	Heterogeneity in tuberculosis. Nature Reviews Immunology, 2017, 17, 691-702.	22.7	379
60	BCG â€" old workhorse, new skills. Current Opinion in Immunology, 2017, 47, 8-16.	5.5	33
61	Immunological characterization of latent tuberculosis infection in a low endemic country. Tuberculosis, 2017, 106, 62-72.	1.9	12
62	Human Genomics of Mycobacterium tuberculosis Infection and Disease. Current Genetic Medicine Reports, 2017, 5, 125-131.	1.9	18
63	Detection of CytosolicShigella flexnerivia a C-Terminal Triple-Arginine Motif of GBP1 Inhibits Actin-Based Motility. MBio, 2017, 8, .	4.1	103
64	Genomics of Human Pulmonary Tuberculosis: from Genes to Pathways. Current Genetic Medicine Reports, 2017, 5, 149-166.	1.9	30
65	Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Nonâ€"Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1529.	7.1	412
66	Novel approaches to tuberculosis vaccine development. International Journal of Infectious Diseases, 2017, 56, 263-267.	3.3	120
67	Transcriptome of blood cells as a reservoir of cardiovascular biomarkers. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 209-216.	4.1	39
68	Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection. Journal of Clinical Microbiology, 2017, 55, 391-402.	3.9	34
69	Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases. Clinical Microbiology and Infection, 2017, 23, 147-153.	6.0	60
70	High-throughput and computational approaches for diagnostic and prognostic host tuberculosis biomarkers. International Journal of Infectious Diseases, 2017, 56, 258-262.	3.3	32
71	Preventive therapy for latent tuberculosis infectionâ€"the promise and the challenges. International Journal of Infectious Diseases, 2017, 56, 68-76.	3.3	118
72	Molecular basis of mycobacterial survival in macrophages. Cellular and Molecular Life Sciences, 2017, 74, 1625-1648.	5.4	110
73	Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When Weâ€™re There?. Journal of Infectious Diseases, 2017, 216, S662-S668.	4.0	17

#	Article	IF	Citations
74	Tuberculosis: Just the FAQs. MBio, 2017, 8, .	4.1	17
75	What We Know About Tuberculosis Transmission: An Overview. Journal of Infectious Diseases, 2017, 216, S629-S635.	4.0	193
76	An alert of <i>Mycobacterium tuberculosis</i> infection of rhesus macaques in a wild zoo in China. Experimental Animals, 2017, 66, 357-365.	1.1	7
77	Human Immunology of Tuberculosis. , 2017, , 213-237.		6
78	Tuberculosis Diagnostics: State of the Art and Future Directions. , 0, , 361-378.		2
79	Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. , 2017, , 379-388.		0
80	The Role of Host Genetics (and Genomics) in Tuberculosis. , 2017, , 411-452.		0
81	Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases. Frontiers in Immunology, 2017, 8, 294.	4.8	56
82	Regulatory T Cells and Pro-inflammatory Responses Predominate in Children with Tuberculosis. Frontiers in Immunology, 2017, 8, 448.	4.8	24
83	What We Have Learned and What We Have Missed in Tuberculosis Pathophysiology for a New Vaccine Design: Searching for the â€œPink Swanâ€• Frontiers in Immunology, 2017, 8, 556.	4.8	29
84	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, 2017, 8, 1203.	4.8	44
85	Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination. Frontiers in Immunology, 2017, 8, 1563.	4.8	18
86	Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological Consequences. Frontiers in Immunology, 2017, 8, 1633.	4.8	91
87	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators of Inflammation, 2017, 2017, 1-15.	3.0	93
88	Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathogens, 2017, 13, e1006687.	4.7	193
89	Diagnosis of Childhood Tuberculosis. , 2017, , .		3
90	Variants of TLR1 associated with tuberculosis susceptibility in the Chinese Tibetan population but not in Han Chinese. Infection, Genetics and Evolution, 2018, 61, 53-59.	2.3	7
91	Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. Respirology, 2018, 23, 455-466.	2.3	150

#	Article	IF	Citations
92	Managing latent tuberculosis infection and tuberculosis in children. Pulmonology, 2018, 24, 106-114.	2.1	31
93	Systems Immunology: Learning the Rules of the Immune System. Annual Review of Immunology, 2018, 36, 813-842.	21.8	70
94	Type I interferons in tuberculosis: Foe and occasionally friend. Journal of Experimental Medicine, 2018, 215, 1273-1285.	8.5	187
95	Diagnosis and therapeutic approach of latent tuberculosis infection. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 302-311.	0.3	2
96	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1198-1208.	5.6	217
97	Diagnostic Test for Incipient Tuberculosis: A Step Forward, Many More to Go. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1106-1107.	5.6	6
98	A Review of Matched-pairs Feature Selection Methods for Gene Expression Data Analysis. Computational and Structural Biotechnology Journal, 2018, 16, 88-97.	4.1	49
99	Discovering transcriptional signatures of disease for diagnosis versus mechanism. Nature Reviews Immunology, 2018, 18, 289-290.	22.7	12
100	Existing blood transcriptional classifiers accurately discriminate active tuberculosis from latent infection in individuals from south India. Tuberculosis, 2018, 109, 41-51.	1.9	51
101	Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E964-E973.	7.1	96
102	Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease. European Respiratory Journal, 2018, 51, 1701578.	6.7	46
103	Potential Diagnostic Power of Blood Circular RNA Expression in Active Pulmonary Tuberculosis. EBioMedicine, 2018, 27, 18-26.	6.1	61
105	DiagnÃ³stico y abordaje terapÃ©utico de la infecciÃ³n tuberculosa latente. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 302-311.	0.5	14
106	T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties. EBioMedicine, 2018, 27, 27-39.	6.1	42
107	Float Like Bacilli, STING Like a B: Type I Interferons in Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 706-707.	5.6	1
108	Prospective Discrimination of Controllers From Progressors Early After Low-Dose Mycobacterium tuberculosis Infection of Cynomolgus Macaques using Blood RNA Signatures. Journal of Infectious Diseases, 2018, 217, 1318-1322.	4.0	13
109	Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. Nature Medicine, 2018, 24, 130-143.	30.7	225
110	Potential Immunological Biomarkers for Detection of Mycobacterium tuberculosis Infection in a Setting Where M. tuberculosis Is Endemic, Ethiopia. Infection and Immunity, 2018, 86, .	2.2	12

#	Article	IF	Citations
111	Tuberculosis eradication: renewed commitment and global investment required. Lancet Infectious Diseases, The, 2018, 18, 228-229.	9.1	9
112	Mycobacterium tuberculosis thymidylate kinase antigen assays for designating incipient, high-risk latent M.tb infection. BMC Infectious Diseases, 2018, 18, 133.	2.9	1
113	High-density lipoprotein suppresses tumor necrosis factor alpha production by mycobacteria-infected human macrophages. Scientific Reports, 2018, 8, 6736.	3.3	23
114	Transcriptional landscape of Mycobacterium tuberculosis infection in macrophages. Scientific Reports, 2018, 8, 6758.	3.3	92
115	Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. Lancet Respiratory Medicine,the, 2018, 6, 246-248.	10.7	11
116	Tuberculosis transmission during the subclinical period: could unrelated cough play a part?. Lancet Respiratory Medicine,the, 2018, 6, 244-246.	10.7	32
117	Transcriptomic Analysis of CD4+ T Cells Reveals Novel Immune Signatures of Latent Tuberculosis. Journal of Immunology, 2018, 200, 3283-3290.	0.8	43
118	Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infectious Diseases, The, 2018, 18, e199-e210.	9.1	244
119	The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction. Clinical Infectious Diseases, 2018, 66, 886-892.	5.8	46
120	Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. Lancet Infectious Diseases, The, 2018, 18, e64-e75.	9.1	119
121	Protein kinase C-delta (PKCÎ´), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice. Mucosal Immunology, 2018, 11, 496-511.	6.0	28
122	Tuberculosis Vaccines. , 2018, , 1095-1113.e9.		3
123	Research and development of new tuberculosis vaccines: a review. F1000Research, 2018, 7, 1732.	1.6	38
124	Paralleling of Diagnostic Endeavor for Control of Mycobacterial Infections and Tuberculosis. , 2018, , .		0
125	Transcriptomic Techniques in Diagnostic Microbiology. , 2018, , 235-259.		0
126	Highlights on the Application of Genomics and Bioinformatics in the Fight Against Infectious Diseases: Challenges and Opportunities in Africa. Frontiers in Genetics, 2018, 9, 575.	2.3	23
127	Diagnosis of HIV-associated tuberculosis. Current Opinion in HIV and AIDS, 2018, 13, 462-468.	3.8	6
128	The Wonder Years: What Can Primary School Children Teach Us About Immunity to Mycobacterium tuberculosis?. Frontiers in Immunology, 2018, 9, 2946.	4.8	64

#	Article	IF	Citations
129	Metabolite changes in blood predict the onset of tuberculosis. Nature Communications, 2018, 9, 5208.	12.8	129
130	The Pathogenesis of Tuberculosis: The Early Infiltrate of Post-primary (Adult Pulmonary) Tuberculosis: A Distinct Disease Entity. Frontiers in Immunology, 2018, 9, 2108.	4.8	67
131	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. Frontiers in Immunology, 2018, 9, 2427.	4.8	43
132	Modeling and analysis of RNAâ€seq data: a review from a statistical perspective. Quantitative Biology, 2018, 6, 195-209.	0.5	49
134	Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study. The Lancet Global Health, 2018, 6, e1329-e1338.	6.3	59
135	Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response. JAMA Network Open, 2018, 1, e183779.	5.9	96
136	Can we predict tuberculosis cure? What tools are available?. European Respiratory Journal, 2018, 52, 1801089.	6.7	73
137	Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for riskÂofÁtuberculosis. European Respiratory Journal, 2018, 52, 1801616.	6.7	3
138	Risk of infection associated with anti-TNF-Î± therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 939-956.	4.4	47
139	Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes. Journal of Controlled Release, 2018, 292, 163-171.	9.9	52
140	The End of the Binary Era: Revisiting the Spectrum of Tuberculosis. Journal of Immunology, 2018, 201, 2541-2548.	0.8	103
141	Progress and challenges in TB vaccine development. F1000Research, 2018, 7, 199.	1.6	93
142	Type 1 interferon-inducible gene expression in QuantiFERON Gold TB-positive uveitis: A tool to stratify a high versus low risk of active tuberculosis?. PLoS ONE, 2018, 13, e0206073.	2.5	6
143	Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy. Frontiers in Immunology, 2018, 9, 2247.	4.8	59
144	Systems approaches to correlates of protection and progression to TB disease. Seminars in Immunology, 2018, 39, 81-87.	5.6	14
145	The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosis. Nature Immunology, 2018, 19, 1159-1168.	14.5	88
146	Cough-aerosol cultures of Mycobacterium tuberculosis in the prediction of outcomes after exposure. A household contact study in Brazil. PLoS ONE, 2018, 13, e0206384.	2.5	18
147	The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy. Frontiers in Microbiology, 2018, 9, 2603.	3.5	56

#	Article	IF	Citations
148	Applying new tools to control tuberculosis. Respirology, 2018, 23, 1114-1116.	2.3	1
149	Recent progress in understanding immune activation in the pathogenesis in HIVâ€“tuberculosis co-infection. Current Opinion in HIV and AIDS, 2018, 13, 455-461.	3.8	12
150	Genetic Resistance to Mycobacterium tuberculosis Infection and Disease. Frontiers in Immunology, 2018, 9, 2219.	4.8	29
151	The Microbiome and Tuberculosis: Early Evidence for Cross Talk. MBio, 2018, 9, .	4.1	71
152	Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment. Vaccines, 2018, 6, 30.	4.4	17
154	Prognostic value of interferon-Î³ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 1077-1087.	9.1	135
155	Addressing diversity in tuberculosis using multidimensional approaches. Journal of Internal Medicine, 2018, 284, 116-124.	6.0	6
156	Perspectives for personalized therapy for patients with multidrugâ€resistant tuberculosis. Journal of Internal Medicine, 2018, 284, 163-188.	6.0	33
157	Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Review of Anti-Infective Therapy, 2018, 16, 501-512.	4.4	53
158	The host response as a tool for infectious disease diagnosis and management. Expert Review of Molecular Diagnostics, 2018, 18, 723-738.	3.1	18
159	Borderline QuantiFERON results and the distinction between specific responses and test variability. Tuberculosis, 2018, 111, 102-108.	1.9	14
160	Correlates of immune exacerbations in leprosy. Seminars in Immunology, 2018, 39, 111-118.	5.6	45
161	Diagnostic Challenge of Tuberculosis Heterogeneity. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 286-296.	2.1	1
162	â€œTuberculosis in advanced HIV infection is associated with increased expression of IFNÎ³ and its downstream targetsâ€• BMC Infectious Diseases, 2018, 18, 220.	2.9	18
163	The Troika Hostâ€“Pathogenâ€“Extrinsic Factors in Tuberculosis: Modulating Inflammation and Clinical Outcomes. Frontiers in Immunology, 2018, 8, 1948.	4.8	24
164	Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmetteâ€“GuÃ©rin-Vaccinated Adults. Frontiers in Immunology, 2018, 9, 564.	4.8	33
165	A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts. Frontiers in Immunology, 2018, 9, 661.	4.8	42
166	Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection. Frontiers in Microbiology, 2018, 9, 1267.	3.5	31

#	Article	IF	Citations
167	Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination. Seminars in Immunology, 2018, 39, 88-101.	5.6	52
168	Evaluating latent tuberculosis infection diagnostics using latent class analysis. Thorax, 2018, 73, 1062-1070.	5.6	36
169	Blood transcriptomic markers of Mycobacterium tuberculosis load in sputum. International Journal of Tuberculosis and Lung Disease, 2018, 22, 950-958.	1.2	7
170	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews, 2018, 31, .	13.6	353
171	Defining a migrant-inclusive tuberculosis research agenda to end TB. International Journal of Tuberculosis and Lung Disease, 2018, 22, 835-843.	1.2	14
172	Macrophage Heterogeneity in the Immunopathogenesis of Tuberculosis. Frontiers in Microbiology, 2018, 9, 1028.	3.5	59
173	Human genetics of mycobacterial disease. Mammalian Genome, 2018, 29, 523-538.	2.2	27
174	Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning. EBioMedicine, 2018, 35, 124-132.	6.1	65
175	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. European Respiratory Journal, 2018, 52, 1800946.	6.7	27
177	Mycobacterium Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following Mycobacterium bovis Bacille Calmetteâ€“GuÃ©rin Vaccination. Frontiers in Immunology, 2018, 9, 1708.	4.8	5
178	A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes. Nature, 2018, 560, 644-648.	27.8	184
179	Where is tuberculosis transmission happening? Insights from the literature, new tools to study transmission and implications for the elimination of tuberculosis. Respirology, 2018, 23, 807-817.	2.3	17
180	Latent tuberculosis infection: Opportunities and challenges. Respirology, 2018, 23, 893-900.	2.3	63
181	Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nature Reviews Immunology, 2018, 18, 575-589.	22.7	241
182	A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. Nature Communications, 2018, 9, 2308.	12.8	142
183	Cytokine biomarkers for the diagnosis of tuberculosis infection and disease in adults in a low prevalence setting. Tuberculosis, 2019, 114, 91-102.	1.9	43
184	The current state of animal models and genomic approaches towards identifying and validating molecular determinants ofMycobacterium tuberculosisinfection and tuberculosis disease. Pathogens and Disease, 2019, 77, .	2.0	32
185	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Scientific Reports, 2019, 9, 11126.	3.3	13

#	Article	IF	Citations
186	Multinomial modelling of TB/HIV co-infection yields a robust predictive signature and generates hypotheses about the HIV+TB+ disease state. PLoS ONE, 2019, 14, e0219322.	2.5	11
187	The Mycobacterial HBHA Protein: A Promising Biomarker for Tuberculosis. Current Medicinal Chemistry, 2019, 26, 2051-2060.	2.4	14
188	Predicting bacterial infection outcomes using single cell RNA-sequencing analysis of human immune cells. Nature Communications, 2019, 10, 3266.	12.8	62
189	Host-Based Diagnostics for Acute Respiratory Infections. Clinical Therapeutics, 2019, 41, 1923-1938.	2.5	13
190	Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies. Lancet Respiratory Medicine,the, 2019, 7, 544-552.	10.7	52
191	Mycobacterium tuberculosisâ€“Induced Bronchoalveolar Lavage Gene Expression Signature in Latent Tuberculosis Infection Is Dominated by Pleiotropic Effects of CD4+ T Cellâ€“Dependent IFN-Î³ Production despite the Presence of Polyfunctional T Cells within the Airways. Journal of Immunology, 2019, 203, 2194-2209.	0.8	13
192	Identification of a systemic interferon-Î³ inducible antimicrobial gene signature in leprosy patients undergoing reversal reaction. PLoS Neglected Tropical Diseases, 2019, 13, e0007764.	3.0	21
193	Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nature Microbiology, 2019, 4, 2128-2135.	13.3	112
194	A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough. Science Translational Medicine, 2019, 11, .	12.4	44
195	Validation of a host response test to distinguish bacterial and viral respiratory infection. EBioMedicine, 2019, 48, 453-461.	6.1	39
196	Tuberculosis Vaccine Development: Progress in Clinical Evaluation. Clinical Microbiology Reviews, 2019, 33, .	13.6	70
197	Diagnosis and management of latent tuberculosis infection in Asia: Review of current status and challenges. International Journal of Infectious Diseases, 2019, 87, 21-29.	3.3	48
198	A qPCR expression assay of IFI44L gene differentiates viral from bacterial infections in febrile children. Scientific Reports, 2019, 9, 11780.	3.3	27
199	Tuberculosis Host-Pathogen Interactions. , 2019, , .		0
200	Challenges and controversies in childhood tuberculosis. Lancet, The, 2019, 394, 967-978.	13.7	54
201	Plasma Type I IFN Protein Concentrations in Human Tuberculosis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 296.	3.9	10
202	Venous Blood-Based Biomarkers in the China Health and Retirement Longitudinal Study: Rationale, Design, and Results From the 2015 Wave. American Journal of Epidemiology, 2019, 188, 1871-1877.	3.4	101
203	Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. American Journal of Epidemiology, 2019, 188, 2078-2085.	3.4	20

#	Article	IF	Citations
204	The evolving research agenda for paediatric tuberculosis infection. Lancet Infectious Diseases, The, 2019, 19, e322-e329.	9.1	19
205	Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study. Cytokine, 2019, 123, 154759.	3.2	55
206	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 1441.	3.5	46
207	Predicting progression to active tuberculosis: A rate-limiting step on the path to elimination. PLoS Medicine, 2019, 16, e1002814.	8.4	8
208	Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol. BMJ Open, 2019, 9, e026612.	1.9	7
209	A Common Variant of ASAP1 Is Associated with Tuberculosis Susceptibility in the Han Chinese Population. Disease Markers, 2019, 2019, 1-7.	1.3	10
210	Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures. PLoS Medicine, 2019, 16, e1002786.	8.4	137
211	Association of the TLR1 variant rs5743557 with susceptibility to tuberculosis. Journal of Thoracic Disease, 2019, 11, 583-594.	1.4	5
212	An Auto-luminescent Fluorescent BCG Whole Blood Assay to Enable Evaluation of Paediatric Mycobacterial Responses Using Minimal Blood Volumes. Frontiers in Pediatrics, 2019, 7, 151.	1.9	9
213	Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. PLoS Medicine, 2019, 16, e1002781.	8.4	72
214	Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. Frontiers in Immunology, 2019, 10, 527.	4.8	40
215	Designing tuberculosis vaccine efficacy trials â€“ lessons from recent studies. Expert Review of Vaccines, 2019, 18, 423-432.	4.4	20
216	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
217	Tuberculosis. Lancet, The, 2019, 393, 1642-1656.	13.7	523
218	Precision medicine in resistant Tuberculosis: Treat the correct patient, at the correct time, with the correct drug. Journal of Infection, 2019, 78, 261-268.	3.3	13
219	Clinical metagenomics. Nature Reviews Genetics, 2019, 20, 341-355.	16.3	793
220	The TAM-TB Assayâ€"A Promising TB Immune-Diagnostic Test With a Potential for Treatment Monitoring. Frontiers in Pediatrics, 2019, 7, 27.	1.9	20
221	Blood Transcriptomic Stratification of Short-term Risk in Contacts of Tuberculosis. Clinical Infectious Diseases, 2020, 70, 731-737.	5.8	66

#	Article	IF	Citations
222	Host Transcriptomics as a Tool to Identify Diagnostic and Mechanistic Immune Signatures of Tuberculosis. Frontiers in Immunology, 2019, 10, 221.	4.8	31
223	Biomarkers for tuberculosis: the case for lipoarabinomannan. ERJ Open Research, 2019, 5, 00115-2018.	2.6	47
224	Factors Associated With Sputum Culture-Negative vs Culture-Positive Diagnosis of Pulmonary Tuberculosis. JAMA Network Open, 2019, 2, e187617.	5.9	28
225	Social determinants of health among residential areas with a high tuberculosis incidence in a remote Inuit community. Journal of Epidemiology and Community Health, 2019, 73, 401-406.	3.7	16
226	A systematic review of biomarkers to detect active tuberculosis. Nature Microbiology, 2019, 4, 748-758.	13.3	146
227	Integrating exosomal microRNAs and electronic health data improved tuberculosis diagnosis. EBioMedicine, 2019, 40, 564-573.	6.1	53
228	Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease. Journal of Experimental Medicine, 2019, 216, 482-500.	8.5	184
229	MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. Journal of Immunology, 2019, 203, 2917-2927.	0.8	55
230	Variable gene expression and parasite load predict treatment outcome in cutaneous leishmaniasis. Science Translational Medicine, 2019, 11, .	12.4	63
231	Epidemiology of Tuberculosis in the United States. Clinics in Chest Medicine, 2019, 40, 693-702.	2.1	23
232	New Concepts in Tuberculosis Host Defense. Clinics in Chest Medicine, 2019, 40, 703-719.	2.1	18
233	Diagnostic Tests for Latent Tuberculosis Infection. Clinics in Chest Medicine, 2019, 40, 829-837.	2.1	42
234	Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study. Scientific Reports, 2019, 9, 17931.	3.3	21
235	Demanding an end to tuberculosis. Current Opinion in HIV and AIDS, 2019, 14, 21-27.	3.8	0
236	Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic Biomarkers That Distinguish Active and Latent Tuberculosis. Frontiers in Immunology, 2019, 10, 2948.	4.8	32
237	Use of Ultra-Deep Sequencing in a Patient with Tuberculous Coxitis Shows Its Limitations in Extrapulmonary Tuberculosis Diagnostics: A Case Report . Infection and Drug Resistance, 2019, Volume 12, 3739-3743.	2.7	5
238	Impact of Aging and HIV Infection on the Function of the C-Type Lectin Receptor MINCLE in Monocytes. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 794-801.	3.6	4
239	Paradigm changing evidence that alter tuberculosis perception and detection: Focus on latency. Infection, Genetics and Evolution, 2019, 72, 78-85.	2.3	4

#	Article	IF	Citations
240	Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. Lancet Infectious Diseases, The, 2019, 19, e65-e76.	9.1	35
241	Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy. ACS Infectious Diseases, 2019, 5, 353-364.	3.8	9
242	Remembering the Host in Tuberculosis Drug Development. Journal of Infectious Diseases, 2019, 219, 1518-1524.	4.0	33
243	Toward the Development of a Circulating Free DNA-Based In Vitro Diagnostic Test for Infectious Diseases: a Review of Evidence for Tuberculosis. Journal of Clinical Microbiology, 2019, 57, .	3.9	60
244	The Global Landscape of Tuberculosis Therapeutics. Annual Review of Medicine, 2019, 70, 105-120.	12.2	24
245	Current approaches toward identifying a correlate of immune protection from tuberculosis. Expert Review of Vaccines, 2019, 18, 43-59.	4.4	18
246	Tuberculosis in Children. Thoracic Surgery Clinics, 2019, 29, 109-121.	1.0	11
247	Advances in the diagnosis, treatment, and prevention of tuberculosis in children. Expert Review of Respiratory Medicine, 2019, 13, 301-311.	2.5	19
248	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 564-571.	5.6	20
249	Tuberculosis Elimination, Research, and Respect for Persons. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 560-563.	5.6	7
250	Sex differences in tuberculosis. Seminars in Immunopathology, 2019, 41, 225-237.	6.1	83
251	Tuberculosis susceptibility and protection in children. Lancet Infectious Diseases, The, 2019, 19, e96-e108.	9.1	76
252	Lipids as Biomarkers of Cancer and Bacterial Infections. Current Medicinal Chemistry, 2019, 26, 1924-1932.	2.4	11
253	Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases. Mucosal Immunology, 2019, 12, 390-402.	6.0	19
254	Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virusâ€“1. Clinical Infectious Diseases, 2019, 69, 295-305.	5.8	10
255	Reply to Singh. Clinical Infectious Diseases, 2020, 71, 471-472.	5.8	3
256	The prescreening tool for gastric cancer in China. Gut, 2020, 69, 1715.2-1715.	12.1	3
257	Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation. Antibiotics, 2020, 9, 21.	3.7	28

#	Article	IF	Citations
258	Two Clinical Prediction Tools to Improve Tuberculosis Contact Investigation. Clinical Infectious Diseases, 2020, 71, e338-e350.	5.8	9
259	Cross-validation of existing signatures and derivation of a novel 29-gene transcriptomic signature predictive of progression to TB in a Brazilian cohort of household contacts of pulmonary TB. Tuberculosis, 2020, 120, 101898.	1.9	20
260	Whole genome profiling refines a panel of correlates to predict vaccine efficacy against Mycobacterium tuberculosis. Tuberculosis, 2020, 120, 101895.	1.9	5
261	Decoding the similarities and specific differences between latent and active tuberculosis infections based on consistently differential expression networks. Briefings in Bioinformatics, 2020, 21, 2084-2098.	6.5	2
262	A systematic review of the impact of psychosocial factors on immunity: Implications for enhancing BCG response against tuberculosis. SSM - Population Health, 2020, 10, 100522.	2.7	10
263	Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up. Expert Review of Respiratory Medicine, 2020, 14, 195-208.	2.5	15
264	Quantitative IFN-Î³ Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis. A Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 984-991.	5.6	29
265	Transcriptomic Profiles of Confirmed Pediatric Tuberculosis Patients and Household Contacts Identifies Active Tuberculosis, Infection, and Treatment Response Among Indian Children. Journal of Infectious Diseases, 2020, 221, 1647-1658.	4.0	16
267	Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers. Cells, 2020, 9, 2160.	4.1	47
268	HIV and the tuberculosis â€œset pointâ€• how HIV impairs alveolar macrophage responses to tuberculosis and sets the stage for progressive disease. Retrovirology, 2020, 17, 32.	2.0	10
269	Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or Mycobacteriu m tuberculosis Infection. Clinical Infectious Diseases, 2021, 73, e3398-e3408.	5.8	18
270	Clinical variables and gene signatures in tuberculosis. Lancet Infectious Diseases, The, 2020, 20, 1227-1229.	9.1	0
271	Blood RNA signatures predict recent tuberculosis exposure in mice, macaques and humans. Scientific Reports, 2020, 10, 16873.	3.3	4
272	An RNA-seq Based Machine Learning Approach Identifies Latent Tuberculosis Patients With an Active Tuberculosis Profile. Frontiers in Immunology, 2020, 11, 1470.	4.8	25
273	A blood RNA transcript signature for TB exposure in household contacts. BMC Infectious Diseases, 2020, 20, 403.	2.9	10
274	Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes. Communications Biology, 2020, 3, 359.	4.4	16
275	Differences in plasma proteomes for active tuberculosis, latent tuberculosis and non-tuberculosis mycobacterial lung disease patients with and without ESAT-6/CFP10 stimulation. Proteome Science, 2020, 18, 10.	1.7	5
276	Robustifying genomic classifiers to batch effects via ensemble learning. Bioinformatics, 2021, 37, 1521-1527.	4.1	13

#	Article	IF	Citations
277	Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Seminars in Immunology, 2020, 50, 101431.	5.6	57
278	Predictive value of TNF-Î±, IFN-Î³, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. BMC Infectious Diseases, 2020, 20, 553.	2.9	6
279	Mucosal delivery of ESX-1â€“expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20848-20859.	7.1	9
280	Perspective for Precision Medicine for Tuberculosis. Frontiers in Immunology, 2020, 11, 566608.	4.8	35
281	The potential of using blood circular RNA as liquid biopsy biomarker for human diseases. Protein and Cell, 2021, 12, 911-946.	11.0	101
282	MCMSeq: Bayesian hierarchical modeling of clustered and repeated measures RNA sequencing experiments. BMC Bioinformatics, 2020, 21, 375.	2.6	9
283	Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0237574.	2.5	39
284	Factors Associated with Mortality in Critically Ill Patients Diagnosed with Hospital Acquired Infections . Infection and Drug Resistance, 2020, Volume 13, 2811-2817.	2.7	2
285	Inverse correlation between serum complement component C1q levels and whole blood typeâ€1 interferon signature in active tuberculosis and QuantiFERONâ€positive uveitis: implications for diagnosis. Clinical and Translational Immunology, 2020, 9, e1196.	3.8	5
286	Distinct Features of Human Myeloid Cell Cytokine Response Profiles Identify Neutrophil Activation by Cytokines as a Prognostic Feature during Tuberculosis and Cancer. Journal of Immunology, 2020, 204, 3389-3399.	0.8	4
287	Distinguishing Kawasaki Disease from Febrile Infectious Disease Using Gene Pair Signatures. BioMed Research International, 2020, 2020, 1-13.	1.9	1
288	Gene Expression: the Key to Understanding HIV-1 Infection?. Microbiology and Molecular Biology Reviews, 2020, 84, .	6.6	9
289	Epigenetic regulation of apoptosis via the PARK7 interactome in peripheral blood mononuclear cells donated by tuberculosis patients vs. healthy controls and the response to treatment: A systems biology approach. Tuberculosis, 2020, 123, 101938.	1.9	1
290	Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota. PLoS Neglected Tropical Diseases, 2020, 14, e0008230.	3.0	14
291	Impact of Intermediate Hyperglycemia and Diabetes on Immune Dysfunction in Tuberculosis. Clinical Infectious Diseases, 2021, 72, 69-78.	5.8	26
292	Latent tuberculosis infection and the EndTB Strategy: ethical tensions and imperatives. International Journal of Tuberculosis and Lung Disease, 2020, 24, 21-26.	1.2	12
293	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. Molecular Immunology, 2020, 120, 187-195.	2.2	19
294	Mouse transcriptome reveals potential signatures of protection and pathogenesis in human tuberculosis. Nature Immunology, 2020, 21, 464-476.	14.5	71

#	Article	IF	Citations
295	Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology. Frontiers in Immunology, 2020, 11, 316.	4.8	59
296	Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study. Lancet Respiratory Medicine,the, 2020, 8, 407-419.	10.7	86
297	Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. Scientific Reports, 2020, 10, 4462.	3.3	13
298	Advances in the diagnosis and treatment of latent tuberculosis infection. Current Opinion in Infectious Diseases, 2020, 33, 166-172.	3.1	12
299	A transcriptional signature accurately identifies Aspergillus Infection across healthy and immunosuppressed states. Translational Research, 2020, 219, 1-12.	5.0	6
300	Preventing tuberculosis in children: A global health emergency. Paediatric Respiratory Reviews, 2020, 36, 44-51.	1.8	9
301	Current and future treatments for tuberculosis. BMJ, The, 2020, 368, m216.	6.0	43
302	Probe Signal Values in mRNA Arrays Imply an Excessive Involvement of Neutrophil FCGR1 in Tuberculosis. Frontiers in Medicine, 2020, 7, 19.	2.6	1
303	Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2020, 115, 340-349.	0.4	37
304	Antibody Fc Glycosylation Discriminates Between Latent and Active Tuberculosis. Journal of Infectious Diseases, 2020, 222, 2093-2102.	4.0	47
305	Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. Lancet Respiratory Medicine,the, 2020, 8, 332-333.	10.7	50
306	Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Frontiers in Microbiology, 2019, 10, 3154.	3.5	56
307	Single-cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis. EBioMedicine, 2020, 53, 102686.	6.1	94
308	Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis â€" End of the road?. International Journal of Infectious Diseases, 2020, 92, S69-S71.	3.3	12
309	Headway made towards biosignatures for incipient tuberculosis. Lancet Respiratory Medicine,the, 2020, 8, 328-330.	10.7	5
310	Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respiratory Medicine,the, 2020, 8, 395-406.	10.7	128
311	Genetics and evolution of tuberculosis pathogenesis: New perspectives and approaches. Infection, Genetics and Evolution, 2020, 81, 104204.	2.3	24
312	Immune correlates of tuberculosis disease and risk translate across species. Science Translational Medicine, 2020, 12, .	12.4	52

#	Article	IF	Citations
313	Latent Tuberculosis Infectionâ€“associated Immunodiagnostic Test Responses as Biomarkers of Incipient Tuberculosis: Fruitful or Futile?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 895-898.	5.6	3
314	Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. European Respiratory Journal, 2020, 55, 1901957.	6.7	30
315	Identification of subclinical tuberculosis in household contacts using exposure scores and contact investigations. BMC Infectious Diseases, 2020, 20, 96.	2.9	14
316	The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection. Frontiers in Immunology, 2020, 11, 669.	4.8	12
317	Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed Controls. Journal of Infectious Diseases, 2020, 222, 995-1007.	4.0	19
318	Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review. Medicina (Lithuania), 2020, 56, 202.	2.0	10
319	A transcriptional blood signature distinguishes early tuberculosis disease from latent tuberculosis infection and uninfected individuals in a Vietnamese cohort. Journal of Infection, 2020, 81, 72-80.	3.3	16
320	The Growing Importance of Tuberculosis Preventive Therapy and How Research and Innovation Can Enhance Its Implementation on the Ground. Tropical Medicine and Infectious Disease, 2020, 5, 61.	2.3	10
321	Ultra-low Dose Aerosol Infection of Mice with Mycobacterium tuberculosis More Closely Models Human Tuberculosis. Cell Host and Microbe, 2021, 29, 68-82.e5.	11.0	62
322	Mycobacterium tuberculosis complex and human coadaptation: a two-way street complicating host susceptibility to TB. Human Molecular Genetics, 2021, 30, R146-R153.	2.9	3
324	Early diagnosis and treatment for SjÃ¶gren's syndrome: current challenges, redefined disease stages and future prospects. Journal of Autoimmunity, 2021, 117, 102590.	6.5	25
325	The paradigm shift in the approach to management of latent tuberculosis infection in high tuberculosis burden countries. Expert Review of Respiratory Medicine, 2021, 15, 899-910.	2.5	1
326	The immune landscape in tuberculosis reveals populations linked to disease and latency. Cell Host and Microbe, 2021, 29, 165-178.e8.	11.0	98
327	Tuberculous Meningitis: Pathogenesis, Immune Responses, Diagnostic Challenges, and the Potential of Biomarker-Based Approaches. Journal of Clinical Microbiology, 2021, 59, .	3.9	29
328	Comparing tuberculosis gene signatures in malnourished individuals using the TBSignatureProfiler. BMC Infectious Diseases, 2021, 21, 106.	2.9	10
329	Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. Clinical Infectious Diseases, 2021, 73, e3384-e3390.	5.8	21
330	Strategies for advanced personalized tuberculosis diagnosis: Current technologies and clinical approaches. Precision Clinical Medicine, 2021, 4, 35-44.	3.3	8
331	High sensitivity and specificity of a 5â€analyte protein and microRNA biosignature for identification of active tuberculosis. Clinical and Translational Immunology, 2021, 10, e1298.	3.8	4

#	Article	IF	Citations
335	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Genome Medicine, 2021, 13, 7.	8.2	193
336	Transcriptional signatures of human peripheral blood mononuclear cells can identify the risk of tuberculosis progression from latent infection among individuals with silicosis. Emerging Microbes and Infections, 2021, 10, 1536-1544.	6.5	4
337	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. European Respiratory Journal, 2021, 58, 2003492.	6.7	27
338	Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young Adults. Frontiers in Immunology, 2021, 12, 639965.	4.8	7
339	Gastrointestinal microbiota composition predicts peripheral inflammatory state during treatment of human tuberculosis. Nature Communications, 2021, 12, 1141.	12.8	28
340	Host Blood RNA Transcript and Protein Signatures for Sputum-Independent Diagnostics of Tuberculosis in Adults. Frontiers in Immunology, 2020, 11, 626049.	4.8	13
341	B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis. Frontiers in Immunology, 2021, 12, 640168.	4.8	49
342	Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points. RNA Biology, 2021, 18, 688-695.	3.1	19
343	A Two-Gene Signature for Tuberculosis Diagnosis in Persons With Advanced HIV. Frontiers in Immunology, 2021, 12, 631165.	4.8	10
344	Chagas Disease in the United States: A Perspective on Diagnostic Testing Limitations and Next Steps. American Journal of Tropical Medicine and Hygiene, 2021, , .	1.4	7
345	Identification of Reduced Host Transcriptomic Signatures for Tuberculosis Disease and Digital PCR-Based Validation and Quantification. Frontiers in Immunology, 2021, 12, 637164.	4.8	25
346	A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection. Frontiers in Immunology, 2021, 12, 634832.	4.8	4
347	Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study. EClinicalMedicine, 2021, 33, 100776.	7.1	26
348	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infectious Diseases, The, 2021, 21, 354-365.	9.1	84
349	Use of a Contained Mycobacterium tuberculosis Mouse Infection Model to Predict Active Disease and Containment in Humans. Journal of Infectious Diseases, 2022, 225, 1832-1840.	4.0	4
350	BCGâ€induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for nextâ€generation vaccines. Immunological Reviews, 2021, 301, 122-144.	6.0	26
351	Meta-Analysis of Peripheral Blood Transcriptome Datasets Reveals a Biomarker Panel for Tuberculosis in Patients Infected With HIV. Frontiers in Cellular and Infection Microbiology, 2021, 11, 585919.	3.9	5
352	Identification of a Minimal 3-Transcript Signature to Differentiate Viral from Bacterial Infection from Best Genome-Wide Host RNA Biomarkers: A Multi-Cohort Analysis. International Journal of Molecular Sciences, 2021, 22, 3148.	4.1	6

#	Article	IF	Citations
355	Transcriptomic signatures have a place in short-term prediction of incident tuberculosis. Lancet Infectious Diseases, The, 2021, 21, 299-300.	9.1	1
356	Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR. Frontiers in Immunology, 2020, 11, 612564.	4.8	16
357	Localized skin inflammation during cutaneous leishmaniasis drives a chronic, systemic IFN-Î³ signature. PLoS Neglected Tropical Diseases, 2021, 15, e0009321.	3.0	17
358	The Innate Immune Response toMycobacterium tuberculosisInfection. Annual Review of Immunology, 2021, 39, 611-637.	21.8	66
359	New Developments and Insights in the Improvement of Mycobacterium tuberculosis Vaccines and Diagnostics Within the End TB Strategy. Current Epidemiology Reports, 2021, 8, 33-45.	2.4	8
360	Immune Subtyping in Latent Tuberculosis. Frontiers in Immunology, 2021, 12, 595746.	4.8	8
361	Whole Blood Mycobacterial Growth Assays for Assessing Human Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 641082.	4.8	4
362	Swarm Learning for decentralized and confidential clinical machine learning. Nature, 2021, 594, 265-270.	27.8	375
363	Transfer transcriptomic signatures for infectious diseases. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
364	Identification of differentially expressed lncRNAs as potential plasma biomarkers for active tuberculosis. Tuberculosis, 2021, 128, 102065.	1.9	8
365	All mycobacteria are inventive, but some are more Daedalean than others. Immunological Reviews, 2021, 301, 5-9.	6.0	0
366	Perspectives for systems biology in the management of tuberculosis. European Respiratory Review, 2021, 30, 200377.	7.1	13
367	Human tuberculosis and Mycobacterium tuberculosis complex: A review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery. Microbiological Research, 2021, 246, 126674.	5.3	55
368	Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?. Frontiers in Immunology, 2021, 12, 703060.	4.8	8
369	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. The Lancet Global Health, 2021, 9, e841-e853.	6.3	34
370	Type I interferon decreases macrophage energy metabolism during mycobacterial infection. Cell Reports, 2021, 35, 109195.	6.4	63
371	Blood RNA signature RISK4LEP predicts leprosy years before clinical onset. EBioMedicine, 2021, 68, 103379.	6.1	29
372	The Evaluation and Validation of Blood-Derived Novel Biomarkers for Precise and Rapid Diagnosis of Tuberculosis in Areas With High-TB Burden. Frontiers in Microbiology, 2021, 12, 650567.	3.5	9

#	Article	IF	Citations
373	Caseâ€“control diagnostic accuracy study of a non-sputum CD38-based TAM-TB test from a single milliliter of blood. Scientific Reports, 2021, 11, 13190.	3.3	14
374	Blood transcriptomic biomarkers for tuberculosis screening: time to redefine our target populations?. The Lancet Global Health, 2021, 9, e736-e737.	6.3	1
375	Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1556-1565.	5.6	25
376	Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoring. Scientific Reports, 2021, 11, 13646.	3.3	20
377	Association between monocyte-to-lymphocyte ratio and tuberculin skin test positivity in HIV-positive adults. PLoS ONE, 2021, 16, e0253907.	2.5	5
378	Reduced thyroxine production in young household contacts of tuberculosis patients increases active tuberculosis disease risk. JCI Insight, 2021, 6, .	5.0	5
380	Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-Î³ release assay conversion. Journal of Clinical Investigation, 2021, 131, .	8.2	13
381	Revisiting the methods for detecting Mycobacterium tuberculosis: what has the new millennium brought thus far?. Access Microbiology, 2021, 3, 000245.	0.5	15
382	Gene Set Enrichment Analysis Reveals Individual Variability in Host Responses in Tuberculosis Patients. Frontiers in Immunology, 2021, 12, 694680.	4.8	5
383	Doxycycline host-directed therapy in human pulmonary tuberculosis. Journal of Clinical Investigation, 2021, 131, .	8.2	27
384	Blood transcriptomics reveal the evolution and resolution of the immune response in tuberculosis. Journal of Experimental Medicine, 2021, 218, .	8.5	36
385	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe, 2021, 17, 210079.	1.3	59
386	Predicting the Survival and Immune Landscape of Colorectal Cancer Patients Using an Immune-Related lncRNA Pair Model. Frontiers in Genetics, 2021, 12, 690530.	2.3	3
387	Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1463-1472.	5.6	15
388	Past and Present Approaches to Diagnosis of Active Pulmonary Tuberculosis. Frontiers in Medicine, 2021, 8, 709793.	2.6	5
389	MicroRNAs to guide medical decision-making in obstructive sleep apnea: A review. Sleep Medicine Reviews, 2021, 59, 101458.	8.5	17
390	CYP2C8 and CYP2E1 genetic variants increase risk of tuberculosis in northwest Chinese Han population. Infection, Genetics and Evolution, 2021, 95, 105022.	2.3	1
391	Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease. Tuberculosis, 2021, 131, 102127.	1.9	13

#	Article	IF	Citations
392	Artificial Intelligence in Blood Transcriptomics. , 2021, , 1-16.		0
393	The Tuberculosis Vaccine Development Pipeline: Present and Future Priorities and Challenges for Research and Innovation. , 2021, , 395-405.		4
394	Pathogenesis and Immunology of Tuberculosis. , 2021, , 19-27.		1
395	The Silent Plague: Regulation of Latent Tuberculosis Infections. , 2019, , 23-42.		1
396	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis, 2018, 109, 61-68.	1.9	28
397	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, 2020, 10, 8629.	3.3	90
398	Whole blood mRNA expression-based targets to discriminate active tuberculosis from latent infection and other pulmonary diseases. Scientific Reports, 2020, 10, 22072.	3.3	10
416	Silicon microneedle array for minimally invasive human health monitoring. , 2018, , .		5
417	Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. JCI Insight, 2019, 4, .	5.0	42
418	The integrated stress response mediates necrosis in murine Mycobacterium tuberculosis granulomas. Journal of Clinical Investigation, 2021, 131, .	8.2	27
419	S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis. Journal of Clinical Investigation, 2020, 130, 3098-3112.	8.2	85
420	Aetiopathogenesis, immunology and microbiology of tuberculosis. , 0, , 62-82.		1
421	What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis. , 0, , 414-429.		1
422	The convergent epidemiology of tuberculosis and human cytomegalovirus infection. F1000Research, 2018, 7, 280.	1.6	19
423	The convergent epidemiology of tuberculosis and human cytomegalovirus infection. F1000Research, 2018, 7, 280.	1.6	31
424	High monocyte to lymphocyte ratio is associated with impaired protection after subcutaneous administration of BCG in a mouse model of tuberculosis. F1000Research, 2018, 7, 296.	1.6	8
425	High monocyte to lymphocyte ratio is associated with impaired protection after subcutaneous administration of BCG in a mouse model of tuberculosis. F1000Research, 2018, 7, 296.	1.6	12
426	Research and development of new tuberculosis vaccines: a review. F1000Research, 2018, 7, 1732.	1.6	27

#	Article	IF	Citations
427	The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Medicine, 2016, 13, e1002152.	8.4	1,305
428	Risk prediction of pulmonary tuberculosis using genetic and conventional risk factors in adult Korean population. PLoS ONE, 2017, 12, e0174642.	2.5	16
429	MAIT cells are reduced in frequency and functionally impaired in human T lymphotropic virus type 1 infection: Potential clinical implications. PLoS ONE, 2017, 12, e0175345.	2.5	33
430	Mycobacterium tuberculosis infection modulates adipose tissue biology. PLoS Pathogens, 2017, 13, e1006676.	4.7	39
431	Latent tuberculosis infection: An overview. Canada Communicable Disease Report, 2017, 43, 62-66.	1.3	120
432	Diagnostic host gene signature for distinguishing enteric fever from other febrile diseases. EMBO Molecular Medicine, 2019, 11, e10431.	6.9	15
434	Genome-wide transcriptional profiling identifies potential signatures in discriminating active tuberculosis from latent infection. Oncotarget, 2017, 8, 112907-112916.	1.8	19
435	Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection. Pathogens and Immunity, 2016, 1, 291.	3.1	18
436	Clinical Application of Interferon-Î³ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence. Pathogens and Immunity, 2016, 1, 308.	3.1	16
437	POTENTIALITIES OF IMMUNOLOGICAL TESTS IN THE DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION AND TUBERCULOSIS. Tuberculosis and Lung Diseases, 2019, 97, 46-58.	0.7	17
438	The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB). Medicina Del Lavoro, 2020, 111, 170-183.	0.4	31
439	Circulating T cell-monocyte complexes are markers of immune perturbations. ELife, 2019, 8, .	6.0	67
440	An evolutionary recent IFN/IL-6/CEBP axis is linked to monocyte expansion and tuberculosis severity in humans. ELife, 2019, 8, .	6.0	27
441	Vaccination Strategies Against Mycobacterium tuberculosis: BCG and Beyond. Advances in Experimental Medicine and Biology, 2021, 1313, 217-240.	1.6	1
442	Overcoming the impacts of two-step batch effect correction on gene expression estimation and inference. Biostatistics, 2023, 24, 635-652.	1.5	11
443	The Intestinal Commensal, Bacteroides fragilis, Modulates Host Responses to Viral Infection and Therapy: Lessons for Exploration during Mycobacterium tuberculosis Infection. Infection and Immunity, 2022, 90, IAI0032121.	2.2	14
444	IFI44L as a Forward Regulator Enhancing Host Antituberculosis Responses. Journal of Immunology Research, 2021, 2021, 1-12.	2.2	15
445	A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction. Tuberculosis, 2021, 131, 102138.	1.9	10

#	Article	IF	Citations
446	Social determinants and BCG efficacy: a call for a socio-biological approach to TB prevention. F1000Research, 2018, 7, 224.	1.6	3
450	Potential Immunology, Transcriptomics and Epigenomic Prediction Tools of the Future to Improve tuberculosis Control. , 2019, , 231-249.		0
454	Gene expression in peripheral blood cells for differentiation of active and latent tuberculosis infection in children and adolescents. Tuberculosis and Lung Diseases, 2020, 97, 28-32.	0.7	0
458	Expressions of miR-29a, TNF-Î± and Vascular Endothelial Growth Factor in Peripheral Blood of Pulmonary Tuberculosis Patients and Their Clinical Significance. Iranian Journal of Public Health, 2020, 49, 1683-1691.	0.5	3
459	Host and Bacterial Iron Homeostasis, an Underexplored Area in Tuberculosis Biomarker Research. Frontiers in Immunology, 2021, 12, 742059.	4.8	8
460	New Insights into the Limitations of Host Transcriptional Biomarkers of Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1363-1365.	5.6	3
461	Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease. Microorganisms, 2021, 9, 2220.	3.6	7
462	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. BMC Medicine, 2021, 19, 252.	5.5	4
463	BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies. , 2020, , 51-62.		0
464	Type I Interferon and Interleukin-1 Driven Inflammatory Pathways as Targets for HDT in Tuberculosis. , 2021, , 219-232.		1
465	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biology, 2020, 18, e3000963.	5.6	6
466	BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies. , 2020, , 1-12.		0
467	Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis. JCI Insight, 2020, 5, .	5.0	5
470	Impact of the interferon-Î³ release assay and glomerular filtration rate on the estimation of active tuberculosis risk before bronchoscopic examinations: a retrospective pilot study. Journal of Thoracic Disease, 2020, 12, 5842-5849.	1.4	1
471	Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages. Frontiers in Immunology, 2021, 12, 712021.	4.8	6
472	Signature required: The transcriptional response to tuberculosis. Journal of Experimental Medicine, 2021, 218, .	8.5	3
473	Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV. EBioMedicine, 2022, 75, 103787.	6.1	12
474	Development and validation of a parsimonious TB gene signature using the digital NanoString nCounter platform. Clinical Infectious Diseases, 2022, , .	5.8	2

#	Article	IF	Citations
475	Impact of the interferon-Î³ release assay and glomerular filtration rate on the estimation of active tuberculosis risk before bronchoscopic examinations: a retrospective pilot study. Journal of Thoracic Disease, 2020, 12, 5842-5849.	1.4	2
477	The Kynurenine/Tryptophan Ratio Is a Sensitive Biomarker for the Diagnosis of Pediatric Tuberculosis Among Indian Children. Frontiers in Immunology, 2021, 12, 774043.	4.8	3
478	Diagnosis of Tuberculosis Infection Activity by Methods of Transcriptional Analysis. Tuberculosis and Lung Diseases, 2022, 99, 57-64.	0.7	0
479	The immunoregulatory landscape of human tuberculosis granulomas. Nature Immunology, 2022, 23, 318-329.	14.5	110
480	Host-pathogen genetic interactions underlie tuberculosis susceptibility in genetically diverse mice. ELife, 2022, 11, .	6.0	44
481	Surface-enhanced Raman spectroscopy of polymerase chain reaction (PCR) products of Rifampin resistant and susceptible tuberculosis patients. Photodiagnosis and Photodynamic Therapy, 2022, 38, 102758.	2.6	15
483	Artificial Intelligence in Blood Transcriptomics. , 2022, , 1109-1123.		0
484	Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes. European Respiratory Journal, 2022, 60, 2102263.	6.7	17
486	Framing the detection of incipient tuberculosis infection: AÂqualitative study of political prioritisation. Tropical Medicine and International Health, 2022, 27, 445-453.	2.3	1
487	Contribution and Future of High-Throughput Transcriptomics in Battling Tuberculosis. Frontiers in Microbiology, 2022, 13, 835620.	3.5	3
488	Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL): A cross-sectional observational study protocol using respondent driven sampling. PLoS ONE, 2022, 17, e0262440.	2.5	1
489	In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion. Frontiers in Immunology, 2022, 13, 853572.	4.8	5
490	Clinical standards for the diagnosis, treatment and prevention of TB infection. International Journal of Tuberculosis and Lung Disease, 2022, 26, 190-205.	1.2	29
492	Transcriptional Profiling and Deriving a Seven-Gene Signature That Discriminates Active and Latent Tuberculosis: An Integrative Bioinformatics Approach. Genes, 2022, 13, 616.	2.4	12
493	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. EBioMedicine, 2022, 77, 103886.	6.1	2
494	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Communications Medicine, 2022, 2, .	4.2	15
495	Clinical predictors of pulmonary tuberculosis among South African adults with HIV. EClinicalMedicine, 2022, 45, 101328.	7.1	7
496	The Biological and Clinical Aspects of a Latent Tuberculosis Infection. Tropical Medicine and Infectious Disease, 2022, 7, 48.	2.3	10

#	Article	IF	Citations
497	Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis. Frontiers in Immunology, 2022, 13, 830482.	4.8	14
498	Surveying the Epigenetic Landscape of Tuberculosis in Alveolar Macrophages. Infection and Immunity, 2022, 90, e0052221.	2.2	8
500	It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity. Frontiers in Immunology, 2022, 13, 840225.	4.8	19
501	Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clinical Microbiology Reviews, 2022, 35, e0022721.	13.6	26
502	Point-of-care diagnostic tests for tuberculosis disease. Science Translational Medicine, 2022, 14, eabj4124.	12.4	18
503	Hostâ€directed antiâ€mycobacterial activity of colchicine, an antiâ€gout drug, via strengthened host innate resistance reinforced by the ILâ€1Î²/PGE₂ axis. British Journal of Pharmacology, 2022, 179, 3951-3969.	5.4	4
504	Impact of STING Inflammatory Signaling during Intracellular Bacterial Infections. Cells, 2022, 11, 74.	4.1	8
505	Importance of next-generation diagnostics in control of tuberculosis in LMICs. EBioMedicine, 2021, 74, 103753.	6.1	4
507	Latent Tuberculosis Infection Diagnosis among Household Contacts in a High Tuberculosis-Burden Area: a Comparison between Transcript Signature and Interferon Gamma Release Assay. Microbiology Spectrum, 2022, 10, e0244521.	3.0	4
508	The Association between Circulating microRNAs and the Risk of Active Disease Development from Latent Tuberculosis Infection: a Nested Case-Control Study. Microbiology Spectrum, 2022, 10, e0262521.	3.0	4
547	Transcriptional Profiles Elucidate Differential Host Responses to Infection with Cryptococcus neoformans and Cryptococcus gattii. Journal of Fungi (Basel, Switzerland), 2022, 8, 430.	3.5	2
548	Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. EClinicalMedicine, 2022, 47, 101396.	7.1	3
549	The clinical application of metagenomic next-generation sequencing for detecting pathogens in bronchoalveolar lavage fluid: case reports and literature review. Expert Review of Molecular Diagnostics, 2022, 22, 575-582.	3.1	7
550	Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition. PLoS ONE, 2022, 17, e0267729.	2.5	2
552	The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study. The Lancet Global Health, 2022, 10, e1034-e1044.	6.3	17
553	Immunopathogenic overlap between COVID-19 and tuberculosis identified from transcriptomic meta-analysis and human macrophage infection. IScience, 2022, 25, 104464.	4.1	19
554	A systematic review on Correlates of Risk of TB disease in children and adults. Indian Journal of Tuberculosis, 2022, , .	0.7	0
555	Isoniazid preventive therapy and TB transcriptional signatures in people with HIV. Aids, 0, Publish Ahead of Print, .	2.2	0

#	Article	IF	Citations
556	Host Transcriptional Signatures Predict Etiology in Community-Acquired Pneumonia: Potential Antibiotic Stewardship Tools. Biomarker Insights, 2022, 17, 117727192210991.	2.5	1
558	Low transcriptomic of PTPRCv1 and CD3E is an independent predictor of mortality in HIV and tuberculosis co-infected patient. Scientific Reports, 2022, 12, .	3.3	0
560	Viral coinfection promotes tuberculosis immunopathogenesis by type I IFN signaling-dependent impediment of Th1 cell pulmonary influx. Nature Communications, 2022, 13, .	12.8	11
561	Mycobacterium tuberculosis infection drives a type I IFN signature in lung lymphocytes. Cell Reports, 2022, 39, 110983.	6.4	20
562	Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 â€“ changing paradigms?. ERJ Open Research, 2022, 8, 00113-2022.	2.6	5
563	Role of GBP1 in innate immunity and potential as a tuberculosis biomarker. Scientific Reports, 2022, 12, .	3.3	6
564	End-point definition and trial design to advance tuberculosis vaccine development. European Respiratory Review, 2022, 31, 220044.	7.1	7
565	Assessment of tuberculosis disease activity in people infected with Mycobacterium tuberculosis and living with HIV: A longitudinal cohort study. EClinicalMedicine, 2022, 49, 101470.	7.1	1
566	Transcriptomics for child and adolescent tuberculosis*. Immunological Reviews, 2022, 309, 97-122.	6.0	17
567	Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review. Frontiers in Immunology, 0, 13, .	4.8	8
568	Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment. EBioMedicine, 2022, 82, 104173.	6.1	5
569	Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic? - A review of evidence and the technological landscape. EBioMedicine, 2022, 82, 104174.	6.1	11
570	Rapid GPR183-mediated recruitment of eosinophils to the lung after Mycobacterium tuberculosis infection. Cell Reports, 2022, 40, 111144.	6.4	20
571	Immune evasion and provocation by Mycobacterium tuberculosis. Nature Reviews Microbiology, 2022, 20, 750-766.	28.6	129
572	The quest for vaccine-induced immune correlates of protection against tuberculosis. , 2022, 1, 165-181.		8
574	Whole transcriptome sequencing reveals neutrophilsâ€™ transcriptional landscape associated with active tuberculosis. Frontiers in Immunology, 0, 13, .	4.8	6
575	Opti-4TB: A protocol for a prospective cohort study evaluating the performance of new biomarkers for active tuberculosis outcome prediction. Frontiers in Medicine, 0, 9, .	2.6	1
577	Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis. Frontiers in Immunology, 0, 13, .	4.8	7

#	Article	IF	Citations
579	Gene expression profiling identifies candidate biomarkers for new latent tuberculosis infections. A cohort study. PLoS ONE, 2022, 17, e0274257.	2.5	1
580	System-wide identification of myeloid markers of TB disease and HIV-induced reactivation in the macaque model of Mtb infection and Mtb/SIV co-infection. Frontiers in Immunology, 0, 13, .	4.8	4
581	T-cell deficiency and hyperinflammatory monocyte responses associate with Mycobacterium avium complex lung disease. Frontiers in Immunology, 0, 13, .	4.8	5
582	Advances in Treatment of Latent TB Infection: What Is the Latest Approach to Treat Latent TB Infection to Prevent Pulmonary TB?. Respiratory Disease Series, 2022, , 217-232.	0.0	0
583	Diagnostic biomarkers for active tuberculosis: progress and challenges. EMBO Molecular Medicine, 2022, 14, .	6.9	18
584	Utility of a three-gene transcriptomic signature in the diagnosis of tuberculosis in a low-endemic hospital setting. Infectious Diseases, 2023, 55, 44-54.	2.8	1
585	Childhood Tuberculosis: Historical Perspectives, Recent Advances, and a Call to Action. Journal of the Pediatric Infectious Diseases Society, 2022, 11, S63-S66.	1.3	0
586	Transcriptional Biomarkers for Treatment Monitoring of Pulmonary Drug-Resistant Tuberculosis: Protocol for a Prospective Observational Study in Indonesia. Tropical Medicine and Infectious Disease, 2022, 7, 326.	2.3	0
587	Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants. Nature Communications, 2022, 13, .	12.8	7
588	Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses. PLoS ONE, 2022, 17, e0276505.	2.5	1
590	Differential expression of host protein biomarkers among symptomatic clinic attendees finally diagnosed with tuberculosis and other respiratory diseases with or without latent Mycobacterium tuberculosis infection. Immunology Letters, 2023, 253, 8-18.	2.5	2
591	miRNA-421 regulates proliferation, migration, and proinflammatory responses of human osteosarcoma cells by targeting monocyte chemotactic protein 1-induced protein 1 protein via magnetic nanoliposomes. Materials Express, 2022, 12, 871-877.	0.5	0
592	Progress on diagnosis and treatment of latent tuberculosis infection. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2022, 51, 691-696.	0.3	0
593	Metabolites enhance innate resistance to human Mycobacterium tuberculosis infection. JCI Insight, 2022, 7, .	5.0	0
595	Neutrophil degranulation, NETosis and platelet degranulation pathway genes are co-induced in whole blood up to six months before tuberculosis diagnosis. PLoS ONE, 2022, 17, e0278295.	2.5	4
596	Immune cell interactions in tuberculosis. Cell, 2022, 185, 4682-4702.	28.9	39
597	Loss of the Immunomodulatory Transcription Factor BATF2 in Humans Is Associated with a Neurological Phenotype. Cells, 2023, 12, 227.	4.1	2
598	Single-cell profiling reveals distinct subsets of CD14+ monocytes drive blood immune signatures of active tuberculosis. Frontiers in Immunology, 0, 13, .	4.8	2

#	Article	IF	Citations
599	T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection. Nature Medicine, 2023, 29, 258-269.	30.7	23
601	Characterizing the Spectrum of LatentMycobacterium tuberculosisin the Cynomolgus Macaque Model: Clinical, Immunologic, and Imaging Features of Evolution. Journal of Infectious Diseases, 2023, 227, 592-601.	4.0	3
603	Host blood-based biosignatures for subclinical TB and incipient TB: A prospective study of adult TB household contacts in Southern India. Frontiers in Immunology, 0, 13, .	4.8	1
604	Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis. EClinicalMedicine, 2023, 56, 101815.	7.1	12
605	QuantiFERON Supernatant-Based Host Biomarkers Predicting Progression to Active Tuberculosis Disease Among Household Contacts of Tuberculosis Patients. Clinical Infectious Diseases, 2023, 76, 1802-1813.	5.8	3
607	Cardiovascular Involvement in Tuberculosis: From Pathophysiology to Diagnosis and Complicationsâ€"A Narrative Review. Diagnostics, 2023, 13, 432.	2.6	11
609	Immunologic, metabolic and genetic impact of diabetes on tuberculosis susceptibility. Frontiers in Immunology, 0, 14, .	4.8	5
610	Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease: A Diagnostic Accuracy Study for Pediatric Tuberculosis. Pediatric Infectious Disease Journal, 2023, 42, 353-360.	2.0	2
612	Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection. Tropical Medicine and Infectious Disease, 2023, 8, 89.	2.3	3
613	Mycobacterium tuberculosis Evasion of Guanylate Binding Protein-Mediated Host Defense in Mice Requires the ESX1 Secretion System. International Journal of Molecular Sciences, 2023, 24, 2861.	4.1	2
614	Systematic review of diagnostic and prognostic host blood transcriptomic signatures of tuberculosis disease in people living with HIV. Gates Open Research, 0, 7, 27.	1.1	0
615	Meeting report: 6th Global Forum on Tuberculosis Vaccines, 22â€"25 February 2022, Toulouse, France. Vaccine: X, 2023, 13, 100267.	2.1	1
616	Research progress on genetic control of host susceptibility to tuberculosis. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2022, 51, 679-690.	0.3	0
617	Pathogenicity of Type I Interferons in Mycobacterium tuberculosis. International Journal of Molecular Sciences, 2023, 24, 3919.	4.1	3
618	A hyperaldosteronism subtypes predictive model using ensemble learning. Scientific Reports, 2023, 13, .	3.3	3
619	TuberculosisXpert - Prediction of Pulmonary Tuberculosis. , 2022, , .		0
621	A united model for diagnosing pulmonary tuberculosis with random forest and artificial neural network. Frontiers in Genetics, 0, 14, .	2.3	1
622	Host Blood Transcriptional Signatures as Candidate Biomarkers for Predicting Progression to Active Tuberculosis. Tuberculosis and Respiratory Diseases, 2023, 86, 94-101.	1.8	2

#	Article	IF	Citations
623	Host determinants of TB disease as targets for HDTs development: A study protocol. Wellcome Open Research, 0, 8, 116.	1.8	0
624	Early Triage of Critically Ill Adult Patients With Mushroom Poisoning: Machine Learning Approach. JMIR Formative Research, 0, 7, e44666.	1.4	2
625	Functions of exosomal non-coding RNAs to the infection with Mycobacterium tuberculosis. Frontiers in Immunology, 0, 14, .	4.8	2
626	Correlates of Protection from Tuberculosis. , 2023, , 99-137.		0
627	Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control. Nature Immunology, 2023, 24, 855-868.	14.5	14
628	Diagnosis and biomarkers for ocular tuberculosis: From the present into the future. Theranostics, 2023, 13, 2088-2113.	10.0	6
630	Genetic epidemiology of resistance to M. tuberculosis Infection: importance of study design and recent findings. Genes and Immunity, 2023, 24, 117-123.	4.1	0
631	Metagenomic next-generation sequencing in osteoarticular infections with a focus on pediatrics: current concepts and clinical applications. EFORT Open Reviews, 2023, 8, 199-212.	4.1	0
632	Predicting Pediatric TB: The Need for Age-specific Host Biosignatures. Clinical Infectious Diseases, 0, , .	5.8	0
633	Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies. Expert Review of Anti-Infective Therapy, 2023, 21, 595-616.	4.4	2
635	RNA sequencing and bioinformatics analysis of differentially expressed genes in the peripheral serum of ankylosing spondylitis patients. Journal of Orthopaedic Surgery and Research, 2023, 18, .	2.3	1
637	Systematic review of diagnostic and prognostic host blood transcriptomic signatures of tuberculosis disease in people living with HIV. Gates Open Research, 0, 7, 27.	1.1	0
638	Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production. Journal of Clinical Investigation, 2023, 133, .	8.2	5
641	Genome-wide screen identifies host loci that modulate Mycobacterium tuberculosis fitness in immunodivergent mice. G3: Genes, Genomes, Genetics, 2023, 13, .	1.8	1
642	Granulocytes subsets and their divergent functions in host resistance to Mycobacterium tuberculosis â€" a â€˜tipping-pointâ€™ model of disease exacerbation. Current Opinion in Immunology, 2023, 84, 102365.	5.5	3
643	Tuberculosis Vaccines. , 2023, , 1158-1176.e8.		0
644	A half-century of research on tuberculosis: Successes and challenges. Journal of Experimental Medicine, 2023, 220, .	8.5	5
646	Role of RIG-I-Like Receptors in the Activation of Innate Immunity in Tuberculosis. Russian Journal of Bioorganic Chemistry, 2023, 49, 742-750.	1.0	0

#	Article	IF	Citations
647	Baseline Cytomegalovirus Viremia at Cryptococcal Meningitis Diagnosis Is Associated With Long-term Increased Incident TB Disease and Mortality in a Prospective Cohort of Ugandan Adults With HIV. Open Forum Infectious Diseases, 2023, 10, .	0.9	1
648	Mycobacterium tuberculosis carrying the rifampicin drug-resistance-conferring rpoB mutation H445Y is associated with suppressed immunity through type I interferons. MBio, 0, , .	4.1	0
649	Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment. PLoS Computational Biology, 2023, 19, e1010770.	3.2	0
650	The interaction of macrophages and CD8 T cells in bronchoalveolar lavage fluid is associated with latent tuberculosis infection. Emerging Microbes and Infections, 2023, 12, .	6.5	3
651	Histoplasma seropositivity in TB patients in The Gambia: Evidence to drive research on a high priority fungal pathogen. Open Forum Infectious Diseases, 0, , .	0.9	0
652	Single-cell RNA-sequencing reveals heterogeneity and intercellular crosstalk in human tuberculosis lung. Journal of Infection, 2023, 87, 373-384.	3.3	1
653	Research tests for the diagnosis of tuberculosis infection. Expert Review of Molecular Diagnostics, 2023, 23, 783-795.	3.1	5
654	Type I interferons and Mycobacterium tuberculosis whole cell lysate induce distinct transcriptional responses in M. tuberculosis infection. Tuberculosis, 2023, 143, 102409.	1.9	0
656	Batch normalization followed by merging is powerful for phenotype prediction integrating multiple heterogeneous studies. PLoS Computational Biology, 2023, 19, e1010608.	3.2	0
657	Vaccine development against tuberculosis before and after Covid-19. Frontiers in Immunology, 0, 14, .	4.8	2
658	BACH1 promotes tissue necrosis and Mycobacterium tuberculosis susceptibility. Nature Microbiology, 0, , .	13.3	1
659	Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries. Lancet Infectious Diseases, The, 2024, 24, 140-149.	9.1	1
661	Distinct gene expression signatures comparing latent tuberculosis infection with different routes of Bacillus Calmette-GuÃ©rin vaccination. Nature Communications, 2023, 14, .	12.8	0
662	A Blood Drying Process for DNA Amplification. Small, 0, , .	10.0	0
663	Tuberculosis prevention: current strategies and future directions. Clinical Microbiology and Infection, 2023, , .	6.0	2
664	The association between phylogenetic lineage and the subclinical phenotype of pulmonary tuberculosis: A retrospective 2-cohort study. Journal of Infection, 2024, 88, 123-131.	3.3	0
665	Omic approaches to infectious disease testing. , 2024, , 1931-1949.		0
666	Reanalysis and validation of the transcriptional pleural fluid signature in pleural tuberculosis. Frontiers in Immunology, 0, 14, .	4.8	0

#	Article	IF	Citations
667	Exposure to Mycobacterium remodels alveolar macrophages and the early innate response to Mycobacterium tuberculosis infection. PLoS Pathogens, 2024, 20, e1011871.	4.7	0
668	The elusive allure of a rapid host blood signature for tuberculosis disease. Journal of Clinical Microbiology, 2024, 62, .	3.9	0
669	IgG glycosylation associates with risk of progression from latent to active tuberculosis. Journal of Infection, 2024, 88, 106115.	3.3	0
670	Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy. Frontiers in Immunology, 0, 15, .	4.8	0
671	Large-scale analysis reveals splicing biomarkers for tuberculosis progression and prognosis. Computers in Biology and Medicine, 2024, 171, 108187.	7.0	0
672	Mycobacterium tuberculosis SecA2-dependent activation of host Rig-I/MAVs signaling is not conserved in Mycobacterium marinum. PLoS ONE, 2024, 19, e0281564.	2.5	0
673	Autophagy promotes efficient T cell responses to restrict high-dose Mycobacterium tuberculosis infection in mice. Nature Microbiology, 2024, 9, 684-697.	13.3	0
675	Current approaches for diagnosis of subclinical pulmonary tuberculosis, clinical implications and future perspectives: a scoping review. Expert Review of Clinical Immunology, 0, , 1-12.	3.0	0
676	Phospholipase C epsilon-1 (PLCÆ1) mediates macrophage activation and protection against tuberculosis. Infection and Immunity, 2024, 92, .	2.2	0
677	A Review Of Host-Specific Diagnostic And Surrogate Biomarkers In Children With Pulmonary Tuberculosis. Paediatric Respiratory Reviews, 2024, , .	1.8	0
678	New framework to define the spectrum of tuberculosis. Lancet Respiratory Medicine,the, 2024, , .	10.7	0